Last reviewed · How we verify
Takecab
Takecab is a Small molecule drug developed by Genuine Research Center, Egypt. It is currently in Phase 1 development for Duodenal ulcer disease, Gastric ulcer, Gastro-esophageal reflux disease with esophagitis.
Vonoprazan, a small molecule, is used to treat various gastrointestinal conditions, including Reflux Esophagitis, Gastroesophageal Reflux Disease, and Gastric/Duodenal Ulcer, among others. It is administered in combination with Amoxicillin 500 mg tid, as seen in clinical trials such as NCT03214081.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Takecab |
|---|---|
| Sponsor | Genuine Research Center, Egypt |
| Target | Potassium-transporting ATPase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Approved indications
- Duodenal ulcer disease
- Gastric ulcer
- Gastro-esophageal reflux disease with esophagitis
- Infection caused by Helicobacter pylori
Common side effects
Key clinical trials
- PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (PHASE4)
- Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
- Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"
- Bioequivalence Study of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan) (PHASE1)
- Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers (PHASE1)
- Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use"
- Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"
- Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Takecab CI brief — competitive landscape report
- Takecab updates RSS · CI watch RSS
- Genuine Research Center, Egypt portfolio CI
Frequently asked questions about Takecab
What is Takecab?
What is Takecab used for?
Who makes Takecab?
What development phase is Takecab in?
What does Takecab target?
Related
- Target: All drugs targeting Potassium-transporting ATPase
- Manufacturer: Genuine Research Center, Egypt — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Duodenal ulcer disease
- Indication: Drugs for Gastric ulcer
- Indication: Drugs for Gastro-esophageal reflux disease with esophagitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing